ArticleFrontiers in bioengineering and biotechnology2025
Enhancing LDD diagnosis with YOLOv9-AID: simultaneous detection of pfirrmann grading, disc herniation, HIZ, and Schmorl's nodules.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study develops an intelligent diagnostic model for LDD based on a novel YOLOv9-AID detection network and evaluates the impact of multiple innovative strategies on detection performance. A total of 222 adult patients who underwent lumbar MRI for low back pain or radicular leg pain were enrolled, yielding 1110 de-identified sagittal T2-weighted images (five per case). After excluding cases with prior spinal trauma, tumors, postoperative changes, congenital malformations, or severe artefacts, 202 cases (1,010 images) were randomly divided into training, validation, and internal test sets (8:1:1), while 20 cases (100 images) formed an external dataset for generalization assessment. The YOLOv9-AID model introduces three key enhancements to the baseline YOLOv9: a SlideLoss function to rebalance training weights between high- and low-quality samples; spatial-channel collaborative attention modules (SCSA) embedded at layers 5 and 11 to strengthen lesion feature extraction; and an ExtraDW-inspired redesign of the ResNCSPELAN4 module to boost precision and reduce parameter count. In the internal test set, the model achieved an mAP50 of 82.8% and an overall detection precision of 80.3%, with Schmorl's node detection at 92.9%, Pfirrmann grading accuracy at 93.3%, and disc herniation accuracy at 73.2% (an 8.4% improvement). Recall rates increased by approximately 5% on average, with Schmorl's node recall up 15.1%, Pfirrmann recall up 1.8%, and herniation recall improvements of up to 12.3%. External validation confirmed robust generalization, and detection rates for small lesions such as high-intensity zones and Schmorl's nodes significantly outperformed conventional methods. These results demonstrate that the YOLOv9-AID network, through the integration of SlideLoss and spatial-channel attention mechanisms, substantially enhances the accuracy and robustness of LDD detection on MRI and offers a promising tool to support clinical diagnosis efficiency and consistency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.